We are live on ! Find out more
HBIO icon

Harvard Bioscience
HBIO

62 hedge funds and large institutions have $55.8M invested in Harvard Bioscience in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 26 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.09% less ownership

Funds ownership: 6.3% → 6.2% (-0.09%)

9% less funds holding

Funds holding: 68 → 62 (-6)

16% less capital invested

Capital invested by funds: $66M → $55.8M (-$10.3M)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

31% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 26

Holders
62
Holders Change
-6
Holders Change %
-8.82%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
18
Reduced
26
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.59M
2
FLAM
First Light Asset Management
Minnesota
+$1.33M
3
BCM
Bridgeway Capital Management
Texas
+$420K
4
AA
Ancora Advisors
Ohio
+$303K
5
HA
Heartland Advisors
Wisconsin
+$288K

Top Sellers

Rank Fund Capital Flow
1
GIM
Granahan Investment Management
Massachusetts
-$1.5M
2
FM
Fondren Management
Texas
-$702K
3
2L
22NW LP
Washington
-$581K
4
JAM
Jupiter Asset Management
United Kingdom
-$204K
5
Invesco
Invesco
Georgia
-$174K
Name Holding Trade Value Shares
Change 		Change in
Stake
MFW
51
Meristem Family Wealth
Minnesota
$32K – – –
Two Sigma Investments
52
Two Sigma Investments
New York
$28K -$288 -10 -0.9%
NFA
53
Nationwide Fund Advisors
Ohio
$23K – – –
JC
54
JBF Capital
Colorado
$16K +$17.9K +620 New
UBS Group
55
UBS Group
Switzerland
$11K -$1.58K -55 -12%
Wells Fargo
56
Wells Fargo
California
$9K – – –
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5K – – –
LTFS
58
Ladenburg Thalmann Financial Services
Florida
$1K – – –
SEI Investments
59
SEI Investments
Pennsylvania
$1K +$230 +8 +28%
Walleye Trading
60
Walleye Trading
New York
$18 -$4.32K -150 -18%
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$5 – – –
FM
62
Fondren Management
Texas
– -$702K -23,000 Closed
2L
63
22NW LP
Washington
– -$581K -19,033 Closed
Invesco
64
Invesco
Georgia
– -$174K -5,703 Closed
JP Morgan Chase
65
JP Morgan Chase
New York
– -$19K -612 Closed
TRCT
66
Tower Research Capital (TRC)
New York
– -$13K -410 Closed
EARNEST Partners
67
EARNEST Partners
Georgia
– -$8K -260 Closed
Deutsche Bank
68
Deutsche Bank
Germany
– -$749 -26 -96%
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
– -$58 -2 -33%
1 2
3

HBIO Hedge Fund Activity: Q1 2017 in Review

62 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2017, worth a combined $55.8M — down 16% from $66M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of HBIO and 5 opened new positions — a net loss of 1 holder — while 26 trimmed existing stakes and 18 added.

The largest buyer was BlackRock, opening a new position worth an estimated $4.59M. The largest seller was Granahan Investment Management, cutting an estimated $1.5M.

  • 62 institutional investors held Harvard Bioscience (HBIO) as of Q1 2017, down from 68 in Q4 2016.
  • Funds reported $55.8M of Harvard Bioscience stock for Q1 2017, down 16% quarter-over-quarter.
  • 5 funds opened new Harvard Bioscience positions in Q1 2017 and 6 closed out, a net change of -1 holder.
  • The largest Harvard Bioscience buyer in Q1 2017 was BlackRock, an estimated $4.59M added.
  • The largest Harvard Bioscience seller in Q1 2017 was Granahan Investment Management, an estimated $1.5M sold.

Based on aggregated 13F filings for Q1 2017.